免疫检查点抑制剂在治疗原发性肝癌中的研究进展

Research Progress of Immune Checkpoint Inhibitors in the Treatment of Primary Liver Cancer

原发性肝癌是全球癌症相关性死亡的重要原因,其往往起病隐匿,发现时已发展至疾病中晚期。传统的靶向药物常常不能满足肝癌患者的临床需求,近年来,肿瘤免疫微环境受到越来越多的关注,免疫检查点抑制剂的出现,带给肝癌患者新的治疗选择。因此,国内外众多学者纷纷开始研究免疫检查点抑制剂的临床获益,相关的临床研究结果也给人以极大的鼓舞。因此,本文将对免疫检查点抑制剂的作用机制及其临床研究进展作一综述。

Primary liver cancer is an important cause of cancer-related death worldwide, and its onset is often insidious, and it has progressed to the middle and late stages of the disease when it is detected. Traditional targeted drugs often cannot meet the clinical needs of liver cancer patients. In recent years, the tumor immune microenvironment has received more and more attention. The emergence of immune checkpoint inhibitors has brought new treatment options for liver cancer patients. Therefore, many scholars at home and abroad have begun to study the clinical benefits of immune checkpoint inhibitors, and the relevant clinical research results are also very encouraging. Therefore, this article will review the mechanism of action of immune checkpoint inhibitors and their clinical research progress.